What is Erdafitinib?

Erdafitinib (Erdafitinib) is an oral small molecule drug that belongs to the category of tyrosine kinase inhibitors. Its main function is to inhibit the activity of fibroblast growth factor receptor (FGFR), thereby blocking the abnormally activated FGFR signaling pathway and inhibiting the growth and spread of cancer cells. FGFR is a type of receptor closely related to cell growth and differentiation, and its abnormal activation is closely related to the occurrence and development of various cancers.

Erdafitinib is commonly used to treat advanced or metastatic urothelial cancer with FGFR gene mutations or activation. Especially for patients for whom classic treatment options fail to provide satisfactory results, erdafitinib provides a targeted treatment option.

Clinical trials showed that erdafitinib showed significant anti-cancer activity in some patients, so it was approved by the U.S. Food and Drug Administration (FDA) in 2019 and became one of the first-line drugs for the treatment of specific types of bladder cancer.

However, similar to other anti-cancer drugs, erdafitinib may also cause some adverse reactions, including but not limited to hypertension, fatigue, hand-foot syndrome, etc. Patients need to closely monitor their physical condition while taking erdafitinib to ensure the efficacy and safety of the drug.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.